• Intellia Therapeutics announced additional positive lonvo-z results for hereditary angioedema, scheduled for presentation at ACAAI on November 13-14, 2026.
• Phase 3 HAELO results showed fewer attacks compared with prior preventive treatment, with improved quality of life versus placebo.
• All treated patients across Phase 1/2 and HAELO studies were free of long-term preventive therapy at their latest follow-up.
• Follow-up extending to four years showed sustained benefit, with no new long-term safety risks identified.
• Preparations are underway for a planned commercial launch of the one-time treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121000PRIMZONEFULLFEED9875790) on November 12, 2026, and is solely responsible for the information contained therein.